Home » Stocks » IVERIC bio

IVERIC bio, Inc. (ISEE)

Stock Price: $4.40 USD -0.14 (-2.98%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $4.54 +0.15 (3.30%) Aug 11, 5:14 PM

Stock Price Chart

Key Info

Market Cap 225.62M
Revenue (ttm) n/a
Net Income (ttm) -65.58M
Shares Out 88.49M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $4.40
Previous Close $4.53
Change ($) -0.14
Change (%) -2.98%
Day's Open 4.66
Day's Range 4.36 - 4.66
Day's Volume 378,800
52-Week Range 0.91 - 8.97

More Stats

Market Cap 225.62M
Enterprise Value n/a
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 88.49M
Float 71.17M
EPS (basic) -1.34
EPS (diluted) -1.33
FCF / Share -0.95
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.30M
Short Ratio 1.07
Short % of Float 3.19%
Beta 2.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.60
Revenue n/a
Operating Income -70.66M
Net Income -65.58M
Free Cash Flow -54.26M
Net Cash 245.59M
Net Cash / Share 4.78
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -24.29%
ROE -38.60%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.00*
(195.79% upside)
Low
11.0
Current: $4.40
High
15.0
Target: 13.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue--21050.9151.5141.26---
Revenue Growth--312.46%-1.16%24.83%----
Gross Profit--21050.9151.5141.26---
Operating Income-61.27-65.35108-196-124-80.51-47.43-13.68-19.63
Net Income-58.8663.09114-193-106-117-51.15-14.56-18.63
Shares Outstanding42.2237.0635.9235.4934.5833.269.001.451.39
Earnings Per Share-1.391.703.17-5.45-3.06-3.51-6.34-14.89-18.27
EPS Growth--46.37%-------
Operating Cash Flow-48.49-41.91-122-109-78.53111-48.78-13.10-19.12
Capital Expenditures0.15---0.57-2.61-1.66-0.01--
Free Cash Flow-48.34-41.91-122-109-81.14109-48.78-13.10-19.13
Cash & Equivalents1261311672892974642114.306.40
Total Debt0.50------11.04-
Net Cash / Debt125131167289297464211-6.746.40
Assets1301371763004294802184.887.73
Liabilities12.9813.2113839436935147.9614.41110
Book Value11712438.04-94.6259.95129170-123-102
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IVERIC bio, Inc.
Country United States
Employees 47
CEO Glenn P. Sblendorio

Stock Information

Ticker Symbol ISEE
Stock Exchange NASDAQ
Sector Services
Industry Specialty Retail, Other
Unique Identifier NASDAQ: ISEE

Description

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.